SkinHealth Systems Inc. (SKIN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 10, 2026, details the results of the Company's Annual Meeting of Stockholders held on that date. The meeting was conducted in a virtual format. As of the record date (April 16, 2026), there were 129,584,184 shares of Class A Common Stock issued and outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Approximately 72.08% of outstanding shares were present virtually or by proxy, establishing a quorum. The following proposals were approved:
- Proposal 1: Election of Nine Directors. All nine nominees were elected to one-year terms expiring at the 2027 annual meeting. Notable vote counts included:
- Pedro Malha: 70,933,549 votes for (1,038,928 withheld).
- Sachin Shridharani, M.D.: 71,317,162 votes for (655,315 withheld).
- Brian Miller: 56,555,107 votes for (15,417,370 withheld).
- Proposal 2: Ratification of Independent Auditor. Stockholders ratified the appointment of Deloitte & Touche LLP for the fiscal year ending December 31, 2026. Votes: 93,125,701 For; 235,673 Against; 45,540 Abstentions.
- Proposal 3: Advisory Vote on Executive Compensation. Stockholders approved the compensation of Named Executive Officers on a non-binding basis. Votes: 58,604,735 For; 12,346,541 Against; 1,021,201 Abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, or specific risk factors. The document serves strictly to report the submission of matters to a vote of security holders.
Key Facts for Investor Verification
- Verify the full biographical details and potential conflicts of interest for the newly elected directors, particularly those with higher "votes withheld" counts (e.g., Brian Miller, E. Scott Beattie).
- Review the Definitive Proxy Statement (Schedule 14A) filed on April 24, 2026, for detailed descriptions of the proposals and executive compensation specifics.
- Confirm the Company's financial performance and liquidity status in the most recent 10-K or 10-Q filings, as this 8-K contains no financial data.
- Note that 21,434,437 shares were recorded as "Broker Non-Votes" for the director election and executive compensation proposals, indicating brokers did not have discretionary voting power on these items.